Hyderabad-based Aurobindo Pharma Ltd announced on Wednesday, July 30, that its wholly owned subsidiary, Aurobindo Pharma USA Inc., has signed a definitive agreement to acquire full ownership of Lannett Company LLC from Lannett Seller Holdco, Inc.
The all-cash transaction, valued at an enterprise value of $250 million (approximately ₹21,850 crore), is based on a cash-free, debt-free structure, including normalized working capital.
Lannett, established in 1942 and headquartered in Trevose, Pennsylvania, is a U.S.-based manufacturer of complex generic pharmaceuticals, with a strong focus on DEA-controlled and non-opioid controlled substances, including treatments for ADHD. The company operates a 425,000 sq. ft. cGMP-compliant manufacturing facility in Seymour, Indiana, with an annual production capacity of around 3.6 billion tablets and a solid regulatory track record.
The acquisition supports Aurobindo’s strategic goal to strengthen its U.S. manufacturing capabilities and expand its product footprint in the U.S. market. It also provides Aurobindo with access to Lannett’s complementary product portfolio, a growing CDMO (Contract Development and Manufacturing Organization) business, and ample manufacturing capacity for future growth.
Currently, Aurobindo has limited presence in the ADHD segment, and this acquisition offers a strategic entry into the high-value therapeutic area. The transaction is pending regulatory clearances, including approval from the U.S. Federal Trade Commission, and is expected to close within 8 to 12 months. The acquisition will be fully funded through internal cash reserves.